FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...

The regulator is due to make a decision on Pfizer’s rival vaccine Abrysvo later this month. Getting FDA approval is just the first hurdle for the two vaccines, however. Assuming they are both ...

If approved, it will be sold as Abrysvo. GSK’s rival vaccine Arexvy became the first RSV vaccine to be cleared by the FDA in this older patient group earlier this month, but maternal use of the ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with ...

Women who are 28-36 weeks pregnant will have access to the Pfizer-made Abrysvo vaccine, which would normally come at a cost of up to $300. Women who are 28-36 weeks pregnant will have access to ...

Women who are 28-36 weeks pregnant will have access to the Pfizer-made Abrysvo vaccine, which would normally come at a cost of up to $300. Founding director of the Immunisation Foundation of ...